{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T20:23:39Z","timestamp":1766348619237},"reference-count":5,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,1,4]],"date-time":"2002-01-04T00:00:00Z","timestamp":1010102400000},"content-version":"vor","delay-in-days":1191,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1998,10]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>Aims<\/jats:italic>\n          <\/jats:bold>\u2007To determine among a cohort of patients newly dispensed a prescription for a proton pump inhibitor (PPI) the extent of prior use of other less expensive agents such as antacids and H<jats:sub>2<\/jats:sub>\u2010receptor antagonists as evidence of a \u2018stepped care\u2019 approach to peptic ulcer and oesophageal disease.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods<\/jats:italic>\n          <\/jats:bold>\u2007A retrospective drug utilization study was conducted within the Pharmaceutical Benefits Scheme (PBS) claims database in Australia. A cohort of social security recipients, who received approval for PPI supply in the month of October 1996, had no prior PPI approval in the previous 18 months and went on to have the drug dispensed, was assembled. This group of \u2018new PPI starters\u2019 was then examined for supply of less expensive prescription medicines to treat peptic ulcer and oesophageal disease in the 12 months prior to obtaining their PPI approval.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Results<\/jats:italic>\n          <\/jats:bold>\u2007In a cohort of 4554 defined new PPI users, 1205 (26.5%) showed no use of H<jats:sub>2<\/jats:sub>\u2010receptor antagonists, antacids, cisapride, cytoprotectants or antiregurgitants in the 12 month period prior to commencing the PPI. The major reason for use given by prescribers for PBS supply was \u2018severe refractory ulcerating oesophagitis\u2019.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusions<\/jats:italic>\n          <\/jats:bold>\u2007Subsidized supply is currently restricted on cost\u2010effectiveness grounds to refractory peptic ulcer disease or severe oesophageal disease. Despite this, utilization and epidemiological data suggest that there is widespread leakage of use outside these indications particularly to less severe forms of oesophageal disease. This patient tracking study has shown within the PBS database that around a quarter of the patients are treated directly with a PPI without being prescribed less expensive agents at least in the preceding 12 months.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1998.00791.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:32:20Z","timestamp":1047357140000},"page":"409-411","source":"Crossref","is-referenced-by-count":21,"title":["Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia"],"prefix":"10.1111","volume":"46","author":[{"given":"Peter","family":"McManus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Marley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald J.","family":"Birkett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,11,14]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199303060-00001"},{"key":"e_1_2_5_3_2","unstructured":"Commonwealth Department of Health and Family ServicesAustralian Statistics on Medicines1996;. Australia Government Publishing Service. Canberra 1998"},{"key":"e_1_2_5_4_2","unstructured":"WHO Collaborating Centre for Drug Statistics MethodologyGuidelines for DDD. Nordic Council on Medicines Oslo1991"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529309096056"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/106002809703100404","article-title":"Extent and variation of omeprazole prescribing in an elderly population of Ontario.","volume":"31","author":"McBride JE","year":"1997","journal-title":"Ann Pharmacother"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1998.00791.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1998.00791.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1998.00791.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T20:01:03Z","timestamp":1698523263000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1998.00791.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,10]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,10]]}},"alternative-id":["10.1046\/j.1365-2125.1998.00791.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00791.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,10]]}}}